Experience
Coalition for Affordable Drugs V LLC
Biogen MA Inc.
A group of hedge funds managed by Kyle Bass filed inter partes review (IPR) petitions challenging two patents covering the multiple sclerosis drug Tecfidera®, held by Finnegan client Biogen MA. Finnegan filed preliminary responses on behalf of Biogen, arguing that the petitions failed to demonstrate that the prior art rendered the claimed inventions obvious, and secured non-institution decisions in both proceedings. The Patent Trial and Appeal Board (PTAB) denied institution on all grounds, concluding that both petitions failed to establish a reasonable likelihood that any of the challenged claims were unpatentable. The PTAB also denied the petitioner’s request for rehearing, which was filed in one of the proceedings. In a third proceeding, the Board issues a final decision confirming patentability.
Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01086, -01136, -01993, PTAB, Judges Gardener-Lane, Katz, Schafer
Coalition for Affordable Drugs IV LLC v. Pharmacyclics, Inc.
AbbVie Inc.; Janssen Biotech, Inc.; Pharmacyclics LLC; Pharmacyclics, Inc.
Finnegan secures a non-institution decision at the PTAB for client iFLY Holdings LLC
iFLY Holdings LLC
Finnegan client AbbVie secures non-institution decisions for Humira® patents
AbbVie Biotechnology, Ltd
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
Joinder and IPR institution denied based on time bar
VirnetX Inc.
Finnegan secures a non-institution decision at the PTAB for Health Diagnostic Laboratory
Health Diagnostic Laboratory, Inc,
AbbVie secures four non-institution decisions for Humira® patent
AbbVie Biotechnology, Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.